Risk factors of mid-term mortality of patients with infective endocarditis.

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
A NomuraK Furukawa

Abstract

In-hospital and long-term mortality of infective endocarditis (IE) are well noted, but the studies for mid-term (90-day) mortality of IE is still limited. We determine the mid-term mortality rate of IE and its significant predictors. Seventy patients with IE were hospitalised at St. Luke's International Hospital between January 1996 and March 2009, of whom 62 consecutive patients could be followed up for 90 days after diagnosis. We then calculated Kaplan-Meier (KM) estimates and performed time-to-event analysis. The mean (standard deviation, SD) age was 66.6 (15.3) years. Thirty-five patients (56%) were male. Blood cultures were positive in 87%. Causative microorganisms were: viridans group streptococci (23%), β-streptococci (16%), Staphylococcus aureus (15%), including methicillin-resistant S. aureus (MRSA) (5%). Thirty-three cases (53%) had at least one complication such as heart failure (34%), central nervous system (CNS) complication (29%) or emboli peripheral to CNS (6%). KM estimates (95% CI) of the 90-day mortality was 14.5% (7.8-25%). In multiple regression analysis using the Cox proportional hazards model, hazard ratios of at least one complication for the 90-day mortality was 8.2 (1.4-155). Mid-term mortality of IE co...Continue Reading

References

Apr 19, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J S LiG R Corey
Feb 5, 2002·Archives of Internal Medicine·Christopher H CabellVance G Fowler
Jan 17, 2002·The New England Journal of Medicine·E Mylonakis, S B Calderwood
Jun 18, 2002·Heart·R O M NetzerC Seiler
Jul 2, 2002·JAMA : the Journal of the American Medical Association·Bruno HoenUNKNOWN Association pour l'Etude et la Prévention de l'Endocardite Infectieuse (AEPEI) Study Group
Oct 3, 2002·Current Opinion in Cardiology·Sonia Jacob, Ann T Tong
Jan 17, 2004·Lancet·Philippe Moreillon, Yok-Ai Que
Mar 24, 2004·Circulation·Vivian H ChuAndrew Wang
Jul 6, 2004·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Samir H HaddadAbdullah A Al-Shimemeri
Jul 20, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·José M MiroUNKNOWN International Collaboration on Endocarditis Merged Database Study Group
Aug 12, 2006·BMJ : British Medical Journal·Rhys P BeynonBernard D Prendergast
Nov 8, 2008·Mayo Clinic Proceedings·Manuel Martínez-SellésUNKNOWN GAME Study Group

❮ Previous
Next ❯

Citations

Nov 19, 2013·BMC Infectious Diseases·Laurenzia FerrarisSpinello Antinori
Apr 30, 2014·Revista Española De Cardiología·Fernando Carrasco-ChinchillaEduardo de Teresa-Galván
Feb 1, 2012·International Journal of Microbiology·Clare PiperR Paul Ross
Nov 12, 2013·Revista Portuguesa De Cardiologia : Orgão Oficial Da Sociedade Portuguesa De Cardiologia = Portuguese Journal of Cardiology : an Official Journal of the Portuguese Society of Cardiology·João Pedro FerreiraJoão Araújo Correia

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Olcay AksoyChristopher H Cabell
© 2021 Meta ULC. All rights reserved